Within a few weeks, Theravance (THRX) will split into two distinct companies: Royalty Management will retain the net operating loss carryforwards, the three programs partnered with GSK and 15% of all other programs the current Theravance is developing. Biopharma will retain the remaining 85% of these programs, $300 million of cash and the entire R&D activities. (Further details have been provided by fellow SA contributor KL Investment Partners in this article.)
As always, biotech companies are very hard to understand and evaluate, and value investors typically avoid the enormous uncertainties surrounding drug pipelines, regulatory approvals, etc. However, there are cases where even value investors have good reasons to invest in this sector, for example, if the price...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|